Beijing Mabworks Biotech is a Chinese developer in Beijing that sponsors 4 registered cancer trials of MBS314 and MBS303.
Beijing Mabworks Biotech appears on ClinicalTrials.gov as the industry sponsor of 4 interventional cancer trials (phase 1/2, 3), testing MBS314, MBS303, Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide, lenalinomide in relapsed or refractory multiple myeloma, non-hodgkin's lymphoma, follicular lymphoma and marginal zone lymphoma. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.